Form 4 for AUPH Aurinia Pharmaceuticals Inc.
Accepted 2024-02-22 00:00:00 ET · period of report 2024-02-20 · accession 0001600620-24-000022 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-02-22 | 2024-02-20 | AUPH | Knappertz Volker | EVP, Research, Development | S - Sale | $5.48 | -25.1K | 324.1K | -7% | -$137.8K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-02-20 | S | D | 25,146 | $5.48 | 324,058 | D | — | — | (F1) Represents the number of shares automatically sold to cover tax withholding obligations in connection with the vesting of RSUs granted on August 1, 2022 grant. (F2) Includes shares of common stock acquired by the reporting person pursuant to the Issuer's 2021 Employee Share Purchase Plan as follows: 2,500 shares of common stock were acquired on May 31, 2023 and 2,430 shares of common stock were acquired on November 30, 2023. |